Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
- 1 October 1994
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 344 (8930) , 1125-1127
- https://doi.org/10.1016/s0140-6736(94)90632-7
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.Proceedings of the National Academy of Sciences, 1994
- New Directions for Biological Therapy in Rheumatoid ArthritisInternational Archives of Allergy and Immunology, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Humanised monoclonal antibody therapy for rheumatoid arthritisThe Lancet, 1992
- Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placeboArthritis & Rheumatism, 1990